SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand - LGND - thread for non-PhDs
LGND 195.83-0.7%Dec 26 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (42)1/30/1997 9:24:00 PM
From: Henry Niman   of 57
 
"Based on results from animal studies, we believe ALRT268 has potential in
non-insulin dependent diabetes mellitus (NIDDM or human type II diabetes),"
Dr. Rosenthale said.
Using two mouse models of NIDDM (the db/db mouse and ob/ob mouse), ALRT268
was compared to treatment with a thiazolidinedione (TZD) which is a member of
a new class of investigational anti-diabetes drug and a control group (15
animals in each group.)
The animals were treated daily with ALRT268 over 14 consecutive days, and
glucose, triglycerides and insulin levels were monitored throughout the
duration of the treatment.

* ALRT268 significantly decreased the levels of blood glucose by 40%,
triglycerides by 45% and insulin by 60%, at the termination of the study.
* ALRT268 maintained the antidiabetic activity during the course of
therapy.
* ALRT268, as a single agent, was as effective as a second generation
TZD.
* ALRT268 demonstrated additive therapeutic effects when administered
with TZD.
* ALRT268 was well tolerated throughout the treatment period.

NIDDM is a metabolic disorder affecting primarily adult individuals and is
characterized by profound changes in glucose regulation and a cascade of
associated hormonal and metabolic disturbances. Elevated levels of glucose
(hyperglycemia) and triglycerides (hypertriglyceridemia) as well as increases
in insulin (hyperinsulinemia) levels due, at least in part, to the ensuing
insulin resistance are part of the metabolic profile seen in these patients.
ALRT268 acts as an insulin sensitizer leading to a significant reduction in
hyperglycemia, hypertriglyceridemia and hyperinsulinemia in animal models of
NIDDM.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News